Gufic BioSciences Ltd (GUFICBIO) — shareholding pattern, promoter holding, financials and share price
About Gufic BioSciences Ltd (GUFICBIO)
Gufic BioSciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GUFICBIO and on the BSE under scrip code 509079. Its ISIN is INE742B01025.
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
Gufic Biosciences Limited is a research‑based pharmaceutical company and one of India’s largest manufacturers of lyophilized injections, operating multiple WHO/EU/ANVISA/MHRA/USFDA‑standard facilities across Navsari, Belgaum and Indore, with domestic branded segments, CMO services, API manufacturing and an expanding international registration footprint across regulated and semi‑regulated markets.
Indore commissioning materially increases global injectable capacity and is being validated via a phased, compliance‑first approach; management expects Indore to be EBITDA breakeven at ~30% utilization and to unlock export volumes that will de‑bottleneck Navsari and lift regulated‑market sales, while they deliberately manage scaling to preserve audit readiness and quality.
Listed peers in Pharmaceuticals: Unichem Laboratories Ltd, Gujarat Themis Biosyn Ltd, SMS Pharmaceuticals Ltd, Novartis India Ltd, Aarti Drugs Ltd, Morepen Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹390.7 a share on 10 Jul 2026, Gufic BioSciences Ltd (GUFICBIO) was valued at a price-to-earnings ratio of 61.02x and a price-to-book of 6.52x on a book value of ₹59.94 per share as of Mar 2025. Solomo computes return on equity of 10.68% and return on capital employed of 13.14% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 61.02x
- P/B
- 6.52x
- EPS (TTM)
- ₹6.4
- Book value / share
- ₹59.94
- ROE
- 10.68%
- ROCE
- 13.14%
- ROA
- 5.49%
- Debt / equity
- 0.56x
- Dividend yield
- 0.03%
- EBITDA margin
- 20.4%
- 52-week range
- ₹280 – ₹685.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Gufic BioSciences Ltd (GUFICBIO) reported revenue of ₹944 crore, net profit of ₹64 crore and earnings per share of ₹6.4. That compares with revenue of ₹820 crore and net profit of ₹70 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹252 crore and net profit ₹22 crore (consolidated).
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 807 | 820 | 944 |
| Net profit (₹ cr) | 86 | 70 | 64 |
| EPS (₹) | 8.59 | 6.95 | 6.4 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 16.09% | 16.69% | 1.71% | 1.63% |
| Profit growth | 28.49% | 25.25% | -9.97% | -19.14% |
| Stock price CAGR | 25% | 16% | 22% | 2% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.5% of Gufic BioSciences Ltd (GUFICBIO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.46% and domestic institutional investors (DII) hold 3.68%. Market capitalisation was ₹3,918 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2003.
Largest disclosed public shareholders in Jun 2026: Motilal Oswal Financial Services Ltd 3.32%, Icici Prudential Multicap Fund 2.02%, Jagdish N Master 1.41%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.5% | - | 0.46% | 3.68% | 27.5% |
| Mar 2026 | 72.5% | - | 0.42% | 3.83% | 27.5% |
| Dec 2025 | 72.5% | - | 0.44% | 3.74% | 27.5% |
| Sep 2025 | 72.5% | - | 0.34% | 3.65% | 27.5% |
| Jun 2025 | 72.51% | - | 0.32% | 3.38% | 27.49% |
| Mar 2025 | 72.51% | - | 0.31% | 3.39% | 27.49% |
| Dec 2024 | 72.51% | - | 0.3% | 2.98% | 27.49% |
| Sep 2024 | 72.51% | - | 0.24% | 2.51% | 27.49% |